@article{91f86e711b92442d9cd781f01e4d262a,
title = "Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease",
abstract = "Objective: Our primary objective was to compare the performance of unaccelerated vs. accelerated structural MRI for measuring disease progression using serial scans in Alzheimer's disease (AD). Methods: We identified cognitively normal (CN), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI) and AD subjects from all available Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects with usable pairs of accelerated and unaccelerated scans. There were a total of 696 subjects with baseline and 3. month scans, 628 subjects with baseline and 6. month scans and 464 subjects with baseline and 12. month scans available. We employed the Symmetric Diffeomorphic Image Normalization method (SyN) for normalization of the serial scans to obtain tensor based morphometry (TBM) maps which indicate the structural changes between pairs of scans. We computed a TBM-SyN summary score of annualized structural changes over 31 regions of interest (ROIs) that are characteristically affected in AD. TBM-SyN scores were computed using accelerated and unaccelerated scan pairs and compared in terms of agreement, group-wise discrimination, and sample size estimates for a hypothetical therapeutic trial. Results: We observed a number of systematic differences between TBM-SyN scores computed from accelerated and unaccelerated pairs of scans. TBM-SyN scores computed from accelerated scans tended to have overall higher estimated values than those from unaccelerated scans. However, the performance of accelerated scans was comparable to unaccelerated scans in terms of discrimination between clinical groups and sample sizes required in each clinical group for a therapeutic trial. We also found that the quality of both accelerated vs. unaccelerated scans were similar. Conclusions: Accelerated scanning protocols reduce scan time considerably. Their group-wise discrimination and sample size estimates were comparable to those obtained with unaccelerated scans. The two protocols did not produce interchangeable TBM-SyN estimates, so it is arguably important to use either accelerated pairs of scans or unaccelerated pairs of scans throughout the study duration.",
author = "{Alzheimer's Disease Neuroimaging Initiative} and Prashanthi Vemuri and Senjem, {Matthew L.} and Gunter, {Jeffrey L.} and Lundt, {Emily S.} and Nirubol Tosakulwong and Weigand, {Stephen D.} and Borowski, {Bret J.} and Bernstein, {Matt A.} and Zuk, {Samantha M.} and Lowe, {Val J.} and Knopman, {David S.} and Petersen, {Ronald C.} and Fox, {Nick C.} and Thompson, {Paul M.} and Weiner, {Michael W.} and Jack, {Clifford R.}",
note = "Funding Information: Data collection and sharing (ADNI data) for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) ( National Institutes of Health Grant U01 AG024904 ) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012 ). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: This work was supported by NIH grants RC2 AG036535 , R00 AG37573 , R01 AG11378 , P50 AG16574 , P50 AG16574/P1 , U01 AG06786 ; the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation , the Elsie and Marvin Dekelboum Family Foundation, U.S.A. and Opus building NIH grant C06 RR018898 . The funding sources were not involved in the manuscript review or approval. ",
year = "2015",
month = jun,
day = "1",
doi = "10.1016/j.neuroimage.2015.03.026",
language = "English (US)",
volume = "113",
pages = "61--69",
journal = "NeuroImage",
issn = "1053-8119",
publisher = "Academic Press Inc.",
}